LGSN

Across TCGA pan-cancer cohorts, LGSN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LGSN data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LGSN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LGSN expression acts as an unfavorable survival marker.

PDAC, HNSC, and LUAD are the cancer types where LGSN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.219	0.915	.006	23	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	6	view →
LUAD	OS	Tertile	III,IV	0.576	1.000	.040	6	view →
LSCC	DFS	Median	III,IV	0.542	0.876	.024	5	view →
GBM	DFS	Tertile	All	0.253	0.518	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LGSN–PDAC (DFS)

Open the PDAC breakdown →